Indicated for the treatment of infections of the skin and skin structure due to susceptible (ONLY ß-lactamase-negative) strains of the following designated microorganisms: Streptococcus spp. (α- and ß-hemolytic strains only), Staphylococcus spp., or E. coli.
►Skin and skin structure infections:
Preservatives may vary across product manufacturers. Consult individual package inserts.
Indicated for the treatment of: skin infections; sinusitis; hordeolum; preseptal cellulitis; dacryocyctitis.
►Skin infections; sinusitis; hordeolum; preseptal cellulitis; dacryocystitis:
Preservatives may vary across product manufacturers. Consult individual package inserts.
Indicated for short-term adjunctive therapy in patients on maximally tolerated medical therapy who require additional intraocular pressure (IOP) reduction. Patients on maximally tolerated medical therapy who are treated with Apraclonidine Ophthalmic Solution to delay surgery should have frequent follow-up examinations and treatment should be discontinued if the IOP rises significantly.
The addition of Apraclonidine Ophthalmic Solution to patients already using two aqueous suppressing drugs (i.e., beta-blocker plus carbonic anhydrase inhibitor) as part of their maximally tolerated medical therapy may not provide additional benefit. This is because Apraclonidine Ophthalmic Solution is an aqueous suppressing drug and the addition of a third aqueous suppressant may not significantly reduce IOP.
The IOP lowering efficacy of Apraclonidine Ophthalmic Solution diminishes over time in some patients. This loss of effect, or tachyphylaxis, appears to be an individual occurrence with a variable time of onset and should be closely monitored. The benefit for most patients is less than 1 month.
►Short-term adjunctive therapy in patients on maximally tolerated medical therapy who require additional reduction of intraocular pressure (IOP):
Preservatives may vary across product manufacturers. Consult individual package inserts.
Indicated for: cycloplegia; mydriasis; penalization of the healthy eye in the treatment of amblyopia.
►Cycloplegia; mydriasis; penalization of the healthy eye in the treatment of amblyopia:
Preservatives may vary across product manufacturers. Consult individual package inserts.
Indicated for the treatment of: skin infections; sinusitis; hordeolum; preseptal cellulitis; dacryocyctitis.
►Skin infections; sinusitis; hordeolum; preseptal cellulitis; dacryocystitis:
None listed in package insert.
Used for the treatment of patients with neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, myopic choroidal neovascularization, or choroidal neovascularization due to presumed ocular histoplasmosis.
►Macular degeneration, wet age-related or choroidal retinal neovascularization:
►Macular edema following retinal vein occlusion:
►Diabetic macular edema or diabetic retinopathy:
None listed in package insert.
Indicated for the treatment of bacterial conjunctivitis caused by susceptible isolates of the following microorganisms: CDC coryneform group G*; Haemophilus influenzae; Staphylococcus aureus; Streptococcus mitis group; Streptococcus pneumonia.
*Efficacy for this orgaeptiblenism was studied in < 10 infections.
►Bacterial conjunctivitis caused by susceptible isolates of the listed microorganisms, recommended:
benzalkonium chloride
Indicated for the treatment of itching of the eye associated with allergic conjunctivitis.
►Itching associated with allergic conjunctivitis, recommended:
Preservatives may vary across product manufacturers. Consult individual package inserts.
Indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms: uncomplicated skin and skin structure infections in adults due to Staphylococcus aureus, Streptococcus pyogenes, or Streptococcus agalactiae. Abscesses usually require surgical drainage. Recommended dosages and durations of therapy in adult and pediatric patient populations vary in these indications.
►Skin/skin structure (uncomplicated):
►Inclusion (chlamydial) conjunctivitis:
►Hordeolum:
Preservatives may vary across product manufacturers. Consult individual package inserts.
Indicated for the treatment of elevated intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma.
Elevated intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma, recommended:
benzalkonium chloride
Indicated for the treatment of superficial ocular infections involving the conjunctiva and/or cornea caused by Bacitracin susceptible organisms.
►Superficial ocular infections involving the conjunctiva and/or cornea caused by susceptible organisms:
Preservatives may vary across product manufacturers. Consult individual package inserts.
Used in the treatment of lacrimal infections, preseptal cellulitis, and/or soft tissue infections.
This medication has a broad FDA approval for the treatment of "infections due to susceptible strains of bacteria." Under our interpretation of this indication we have linked this medication with conditions we understand may be "infections due to susceptible strains of bacteria." This is our medical opinion and may not be true in all clinical circumstances.
►Lacrimal infections, preseptal cellulitis, and/or soft tissue infections, recommended:
alcohol, methylparaben, sodium benzoate (oral suspension); sodium benzoate (tablets).
Indicated for the treatment of neovascular (wet) age-related macular degeneration.
►Neovascular (wet) age-related macular degeneration, recommended:
None listed in package insert.
Indicated for the treatment of itching associated with signs and symptoms of allergic conjunctivitis.
►Itching associated with allergic conjunctivitis:
benzalkonium chloride
Indicated for the treatment of bacterial conjunctivitis caused by susceptible isolates of the following bacteria: Aerococcus viridians*; CDC coryneform group G; Corynebacterium pseudodiphtheriticum*; Corynebacterium striatum*; Haemophilus influenzae; Moraxella catarrhalis*; Moraxella lacunata*; Pseudomonas aeruginosa*; Staphylococcus aureus; Staphylococcus epidermidis; Staphylococcus hominis*; Staphylococcus lugdunensis*; Staphylococcus warneri*; Streptococcus mitis group; Streptococcus oralis; Streptococcus pneumoniae; Streptococcus salivarius*.
*Efficacy for this organism was studied in fewer than 10 infections
►Bacterial conjunctivitis caused by susceptible isolates of the listed bacteria:
benzalkonium chloride
Indicated for prepping of the periocular region (lids, brow, and cheek) and irrigation of the ocular surface (cornea, conjunctiva, and palpebral fornices).
►Prepping of the periocular region (lids, brow, and cheek) and irrigation of the ocular surface (cornea, conjunctiva, and palpebral fornices):
None listed in package insert.
Has been shown to be effective in lowering intraocular pressure (IOP) and may be used in patients with chronic open-angle glaucoma or ocular hypertension.
►Elevated intraocular pressure (IOP) in patients with chronic open-angle glaucoma or ocular hypertension, recommended:
benzalkonium chloride
Indicated for the treatment of ocular hypertension and chronic open-angle glaucoma. It may be used alone or in combination with other anti-glaucoma drugs.
►Elevated intraocular pressure (IOP) in patients with ocular hypertension or chronic open-angle glaucoma, recommended:
Preservatives may vary across product manufacturers. Consult individual package inserts.
Indicated for the treatment of elevated intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma.
►Elevated intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma, recommended:
benzalkonium chloride
Indicated for the treatment of elevated intraocular pressure (IOP) in patients with chronic open-angle glaucoma or ocular hypertension.
►Elevated intraocular pressure (IOP) in patients with chronic open-angle glaucoma or ocular hypertension:
benzalkonium chloride
Store upright at 36° – 77°F (2° – 25°C).